Your browser doesn't support javascript.
Phage therapeutics: from promises to practices and prospectives.
Bhargava, Kanika; Nath, Gopal; Bhargava, Amit; Aseri, G K; Jain, Neelam.
  • Bhargava K; Amity Institute of Microbial Technology, Amity University Rajasthan, Jaipur, 303 002, India.
  • Nath G; Department of Microbiology, IMS, Banaras Hindu University, Varanasi, 221005, India.
  • Bhargava A; Department of Microbiology, IMS, Banaras Hindu University, Varanasi, 221005, India.
  • Aseri GK; Department of Medicine, Hayes Memorial Hospital, SHUATS, Allahabad, 211007, India.
  • Jain N; Amity Institute of Microbial Technology, Amity University Rajasthan, Jaipur, 303 002, India.
Appl Microbiol Biotechnol ; 105(24): 9047-9067, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1530288
ABSTRACT
The rise in multi-drug resistant bacteria and the inability to develop novel antibacterial agents limits our arsenal against infectious diseases. Antibiotic resistance is a global issue requiring an immediate solution, including the development of new antibiotic molecules and other alternative modes of therapy. This article highlights the mechanism of bacteriophage treatment that makes it a real solution for multidrug-resistant infectious diseases. Several case reports identified phage therapy as a potential solution to the emerging challenge of multi-drug resistance. Bacteriophages, unlike antibiotics, have special features, such as host specificity and do not impact other commensals. A new outlook has also arisen with recent advancements in the understanding of phage immunobiology, where phages are repurposed against both bacterial and viral infections. Thus, the potential possibility of phages in COVID-19 patients with secondary bacterial infections has been briefly elucidated. However, significant obstacles that need to be addressed are to design better clinical studies that may contribute to the widespread use of bacteriophage therapy against multi-drug resistant pathogens. In conclusion, antibacterial agents can be used with bacteriophages, i.e. bacteriophage-antibiotic combination therapy, or they can be administered alone in cases when antibiotics are ineffective.Key points• AMR, a consequence of antibiotic generated menace globally, has led to the resurgence of phage therapy as an effective and sustainable solution without any side effects and high specificity against refractory MDR bacterial infections.• Bacteriophages have fewer adverse reactions and can thus be used as monotherapy as well as in conjunction with antibiotics.• In the context of the COVID-19 pandemic, phage therapy may be a viable option.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Bacteriophages / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: Appl Microbiol Biotechnol Year: 2021 Document Type: Article Affiliation country: S00253-021-11695-z

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Bacteriophages / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: Appl Microbiol Biotechnol Year: 2021 Document Type: Article Affiliation country: S00253-021-11695-z